docetaxel anhydrous has been researched along with Bile Duct Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Du, N; Li, XS; Ma, HY; Song, LP; Wan, L; Wang, L; Zhao, H | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J | 1 |
| Burris, HA; Hoff, PM; Patt, YZ; Pazdur, R; Rinaldi, DA; Rodriguez, GI; Royce, ME | 1 |
1 review(s) available for docetaxel anhydrous and Bile Duct Neoplasms
| Article | Year |
|---|---|
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
2 trial(s) available for docetaxel anhydrous and Bile Duct Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leukopenia; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Phase II trial of docetaxel for cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
2 other study(ies) available for docetaxel anhydrous and Bile Duct Neoplasms
| Article | Year |
|---|---|
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
Novel pH-sensitive nanoformulated docetaxel as a potential therapeutic strategy for the treatment of cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Chondroitin Sulfates; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Delivery Systems; Histamine; Humans; Hydrogen-Ion Concentration; Mice, Nude; Micelles; Nanocomposites; Taxoids; Xenograft Model Antitumor Assays | 2015 |